These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 28121221)

  • 1. The association between circulating tumor cells and Epstein-Barr virus activation in patients with nasopharyngeal carcinoma.
    He C; Huang X; Su X; Tang T; Zhang X; Ma J; Guo X; Lv X
    Cancer Biol Ther; 2017 Nov; 18(11):888-894. PubMed ID: 28121221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Correlations among Circulating Tumor Cells, Epstein-Barr Virus Status, and Epidemiology in Patients with Nasopharyngeal Carcinoma.
    Dong L; Luo Y; Li Y; Qin W; Cheng Y; Liu J; Zhang Z; Wang Z; Li H; Li S; Zhou X; Cai Y
    Clin Lab; 2022 Oct; 68(10):. PubMed ID: 36250833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of circulating tumor cells and their expression of cyclooxygenase-2 in patients with nasopharyngeal carcinoma.
    Xie XQ; Luo Y; Ma XL; Li SS; Liu L; Zhang H; Li P; Wang F
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6951-6961. PubMed ID: 31486495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor cells with karyotyping as a novel biomarker for diagnosis and treatment of nasopharyngeal carcinoma.
    Zhang J; Shi H; Jiang T; Liu Z; Lin PP; Chen N
    BMC Cancer; 2018 Nov; 18(1):1133. PubMed ID: 30454007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of circulating tumor cells and Epstein-Barr virus DNA to progression-free survival and overall survival in metastatic nasopharyngeal carcinoma patients.
    You R; Liu YP; Lin M; Huang PY; Tang LQ; Zhang YN; Pan Y; Liu WL; Guo WB; Zou X; Zhao KM; Kang T; Liu LZ; Lin AH; Hong MH; Mai HQ; Zeng MS; Chen MY
    Int J Cancer; 2019 Nov; 145(10):2873-2883. PubMed ID: 31044420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of VCA (viral capsid antigen) and EBNA1 (Epstein-Barr-virus-encoded nuclear antigen 1) genes of Epstein-Barr virus in Pichia pastoris and application of the products in a screening test for patients with nasopharyngeal carcinoma.
    Hu B; Hong G; Li Z; Xu J; Zhu Z; Li L
    Biotechnol Appl Biochem; 2007 May; 47(Pt 1):59-69. PubMed ID: 17129209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody.
    Leung SF; Tam JS; Chan AT; Zee B; Chan LY; Huang DP; Van Hasselt A; Johnson PJ; Lo YM
    Clin Chem; 2004 Feb; 50(2):339-45. PubMed ID: 14684618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Plasma Epstein-Barr Virus LMP1 and EBER1 with Circulating Tumor Cells and the Metastasis of Nasopharyngeal Carcinoma.
    Sun L; Wang Y; Shi J; Zhu W; Wang X
    Pathol Oncol Res; 2020 Jul; 26(3):1893-1901. PubMed ID: 31832991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma.
    Shao JY; Huang XM; Yu XJ; Huang LX; Wu QL; Xia JC; Wang HY; Feng QS; Ren ZF; Ernberg I; Hu LF; Zeng YX
    Anticancer Res; 2001; 21(4B):3021-9. PubMed ID: 11712805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The interaction and mediation effects between the host genetic factors and Epstein-Barr virus VCA-IgA in the risk of nasopharyngeal carcinoma.
    Diao H; Xue WQ; Wang TM; Yang DW; Deng CM; Li DH; Zhang WL; Liao Y; Wu YX; Chen XY; Zhou T; Li XZ; Zhang PF; Zheng XH; Zhang SD; Hu YZ; Cao SM; Liu Q; Ye WM; He YQ; Jia WH
    J Med Virol; 2023 Nov; 95(11):e29224. PubMed ID: 37970759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
    Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
    J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosomal cyclophilin A as a novel noninvasive biomarker for Epstein-Barr virus associated nasopharyngeal carcinoma.
    Liu L; Zuo L; Yang J; Xin S; Zhang J; Zhou J; Li G; Tang J; Lu J
    Cancer Med; 2019 Jun; 8(6):3142-3151. PubMed ID: 31063269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr virus (EBV) latent membrane protein 1 induces interleukin-8 through the nuclear factor-kappa B signaling pathway in EBV-infected nasopharyngeal carcinoma cell line.
    Ren Q; Sato H; Murono S; Furukawa M; Yoshizaki T
    Laryngoscope; 2004 May; 114(5):855-9. PubMed ID: 15126743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymyositis/dermatomyositis and nasopharyngeal carcinoma: the Epstein-Barr virus connection?
    Chen DY; Chen YM; Lan JL; Chen HH; Hsieh CW; Wey SJ; Lu JJ
    J Clin Virol; 2010 Dec; 49(4):290-5. PubMed ID: 20934910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Circulating Tumour Cells and Circulating Cell-Free Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Undergoing Radiotherapy.
    Vo JH; Nei WL; Hu M; Phyo WM; Wang F; Fong KW; Tan T; Soong YL; Cheah SL; Sommat K; Low H; Ling B; Ng J; Tan WL; Chan KS; Oon L; Ying JY; Tan MH
    Sci Rep; 2016 Dec; 6(1):13. PubMed ID: 28442757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemokine CCL27 is a novel plasma biomarker for identification the nasopharyngeal carcinoma patients from the Epstein-Barr virus capsid antigen-specific IgA seropositive population.
    Mao MJ; Xue N; Wang XP; Chi PD; Liu YJ; Huang Q; Dai SQ; Liu WL
    BMC Cancer; 2018 Jan; 18(1):9. PubMed ID: 29295705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel biomarkers of nasopharyngeal carcinoma metastasis risk identified by reverse phase protein array based tumor profiling with consideration of plasma Epstein-Barr virus DNA load.
    Xu T; Su B; Huang P; Wei W; Deng Y; Sehgal V; Wang D; Jiang J; Zhang G; Li A; Yang H; Claret FX
    Proteomics Clin Appl; 2017 May; 11(5-6):. PubMed ID: 27883284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reactive nitrogen species-dependent DNA damage in EBV-associated nasopharyngeal carcinoma: the relation to STAT3 activation and EGFR expression.
    Ma N; Kawanishi M; Hiraku Y; Murata M; Huang GW; Huang Y; Luo DZ; Mo WG; Fukui Y; Kawanishi S
    Int J Cancer; 2008 Jun; 122(11):2517-25. PubMed ID: 18307254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
    Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.